Physiomics PLC Issue of Equity and Director Dealing (1351V)
05 Agosto 2020 - 01:00AM
UK Regulatory
TIDMPYC
RNS Number : 1351V
Physiomics PLC
05 August 2020
5 August 2020
Physiomics plc
("Physiomics" or "the Company")
Issue of Equity and Director Dealing
Physiomics plc, a provider of technology-based solutions to
predict the effects of cancer treatment regimens for the biopharma
industry, announces that following the receipt of notices of
exercise of employee options, 1,655,813 ordinary shares of 0.4p
each in the Company ("Ordinary Shares") (the "Options Shares") have
now been issued to the following employees at the following
exercise prices:
Number of Options Exercise price
Grantee Shares issued per option
Dr J Millen, CEO 1,453,923 2.5p
------------------ ---------------
Other staff 201,890 2.5p
------------------ ---------------
Application will be made for the Option Shares to be admitted to
trading on AIM, and dealings in the Option Shares are expected to
commence on 11 August 2020 ("Admission"). Following Admission, the
total number of Ordinary Shares in issue will increase to
97,244,778.
For the purposes of the Financial Services Authority's
Disclosure Guidance and Transparency Rules (the "DTRs"), the issued
ordinary share capital of the Company following Admission will
consist of 97,244,778 Ordinary Shares with voting rights attached
(one vote per Ordinary Share). There are no Ordinary Shares held in
treasury. This total voting rights figure may be used by
shareholders as the denominator for the calculations by which they
will determine whether they are required to notify their interests
in, or a change to their interest in, Physiomics under the DTRs.
The Company's share capital additionally comprises 2,481,657,918
deferred shares of 0.036p each which are not quoted and to which no
voting rights attach.
Following Admission, Dr Millen will be interested in 1,984,279
Ordinary Shares, representing approximately 2.04% of the Company's
then issued share capital.
The information contained within this announcement is deemed by
the Company to constitute inside information under the Market Abuse
Regulation (EU) No. 596/2014.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name James Millen
------------------------------------------------------------ ----------------------------------------
2 Reason for the notification
------------------------------------------------------------------------------------------------------
a) Position/status Director, CEO
------------------------------------------------------------ ----------------------------------------
b) Initial notification/ Amendment Initial notification
------------------------------------------------------------ ----------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
------------------------------------------------------------------------------------------------------
a) Name Physiomics plc
------------------------------------------------------------ ----------------------------------------
b) LEI 213800A71DSZ6ABMTQ91
------------------------------------------------------------ ----------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument Exercise of options over Ordinary share
Identification code
GB00BDR6W943
------------------------------------------------------------ ----------------------------------------
b) Nature of the transaction Exercise of options over Ordinary share
------------------------------------------------------------ ----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
2.5p 1,453,923
----------
------------------------------------------------------------ ----------------------------------------
d) Aggregated information
* Aggregated volume 1,453,923
At 2.5p per share
* Price
------------------------------------------------------------ ----------------------------------------
e) Date of the transaction 5 August 2020
------------------------------------------------------------ ----------------------------------------
f) Place of the transaction Outside of trading venue
------------------------------------------------------------ ----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCPIMFTMTTMBFM
(END) Dow Jones Newswires
August 05, 2020 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024